Maintaining an Effective CAPA Program and Using Risk Assessment Tools: Current Trends - By AtoZ Compliance

MessageThis Webinar is over
Date Mar 15, 2016
Time 01:00 PM EDT
Cost $155.00
Key Take Away
Get an overview on the current trends in identifying recommended practices to improve, streamline, refine, retool, develop, deploy and maintain a viable and sustainable CAPA system.

CAPA programs are critical for any manufacturer. FDA considers your program the immune system for your site business unit and determines how healthy or unhealthy you are. Industry is now using various risk-based approaches and tools to set-up, deploy and maintain their CAPA training to help with the decision making process.
Why Should You Attend
This webinar provides an overview on identifying recommended practices to improve, streamline, refine, retool and develop, deploy and maintain a viable and sustainable CAPA system. 
Learn that a well written policy and procedure on setting up and maintaining your system is just the first part of the process, now you need to monitor your system because CAPA is your immune system and will determine how healthy or unhealthy or business site is.
Areas Covered In This Webinar
Understand the emphasis on analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other risk assessment tools and quality problems and the use of appropriate statistical methodology where necessary to detect recurring quality problems.
Learning Objectives
  • How to use FMEA training effectively and calculating Risk Priority Numbers: How to use the criteria
  • How to facilitate a product complaint investigation as part of your CAPA program
  • What is a closed-loop investigation…cradle to grave approach
  • How to conduct an investigation using a well-written CAPA policy and failure mode effect analysis
  • Understand and comprehend what FDA is looking for in meeting minimum expectations…no band-aid solutions
  • Why risk assessment and risk-based approaches, FMEA, FTA, HACCP, etc., are now the expectation in terms of good business practice
  • Establish a priority system as related to major versus minor or high risk versus low risk classifications…to support your decisions
  • Develop and deploy escalation rules and criteria to facilitate decision-making process
  • Understand what it takes to conduct a “quality” investigation to ascertain the root cause
  • Review and discuss recent CAPA red flags and FDA enforcement actions

Who Will Benefit
  • All levels of Management for all Departments
  • QA/QC/CAPA Coordinators
  • CAPA Specialists
  • Regulatory Affairs and Compliance Professionals
  • Engineering/Technical Services/Operations Personnel
  • Consultants

Speakers Profile
David R Dills
David R. Dills, is an independent Global Regulatory Affairs & Compliance Consultant and has an accomplished record with more than 26 years of experience in regulatory affairs, compliance and quality consultative services for early-stage/established Class I/II/III medical devices, IVD's, and bio/pharmaceutical manufacturers on the global landscape.
Previously employed, with increasing responsibilities by device manufacturers and consultancies, including a globally recognized CRO, has worked directly with and for manufacturers engaged in compliance remediation activities involving consent decrees, CIA’s, FDA warning letters, and customer generated compliance events, provides Strategic GxP Compliance and Regulatory Consulting, handles all aspects of global regulatory submissions and dossiers, including 510(k), PMA and IDE submissions, serves as a U.S. Agent, works with stakeholders and Center Reviewers regarding submission meetings/negotiations, clinical affairs, and provides regulatory submissions and post-market project leadership/guidance covering different therapeutic and medical specialties based on classification. Background encompasses broad capabilities in regulatory and compliance oversight and governance, regulatory and GxP training, and compliance with MEDDEV/MDD/IVDD Directives.
Mr. Dills leads and manages efforts involving multi-country product registrations and licensing in Asia Pacific, EU and The Americas from premarketing to postmarketing, and works with the Regulatory Authorities and strives to provide consistent, practical compliance solutions that work with reduction of regulatory compliance risk.

For more detail please click on this below link:

Toll Free: +1- 844-414-1400
Tel: +1-516-900-5509


Create your own event
Turn your passion into a business.
Join our mailing list